Many biosimilar developers need to think outside the box when structuring their clinical trials. As an example, one could discuss with a supervisor whether it is insufficient to investigate only one indication in the comparative efficacy study and rely on extrapolation for the remaining indications.
Learning curves in the current clinical biosimilar development
May 20, 2020 | Registration Process